Three Healthcare Giants Racing to Replace Their Biggest Drugs

Every major drugmaker eventually faces the same problem: its best-selling medicines lose patent protection, and generic competition follows. The companies that thrive are the ones that have new products ready before that day arrives.

Three large healthcare names are in the middle of that race right now. Each pays a dividend that sits well above what the broader market offers, and each has a clear plan for what comes next. Looking at what each one has to replace, and what it has in hand to do it, shows how durable those payouts may be.

Bristol Myers Squibb (BMY): Replacing Eliquis and Opdivo

Bristol Myers faces two big patent challenges. It co-markets the blood thinner Eliquis, which is heading toward a patent cliff, and its cancer drug Opdivo, a longtime growth driver, will lose exclusivity by the end of the decade.

The company is not waiting. Third-quarter revenue rose 7% to $13.1 billion, and its growth portfolio, made up mostly of newer medicines, brought in $7.7 billion, up 12%. A newer subcutaneous version of Opdivo, which is faster to administer, is already on the market and gaining traction. Several pipeline candidates could also help fill the gap left by Eliquis.

The dividend yield is above average, which reflects how much the market worries about those cliffs.

Pfizer (PFE): Outgrowing Eliquis and Ibrance

Pfizer shares the Eliquis challenge with Bristol Myers and also faces a cliff on its cancer drug Ibrance. Years of pressure on the stock have pushed its dividend yield well above the market average. A high yield is only meaningful if the payout holds, and Pfizer has not cut its dividend through this stretch.

Headline numbers look slow. Third-quarter revenue of $16.6 billion was flat from a year earlier, but revenue excluding its coronavirus products rose 7%. Its launched and acquired products grew sales 32%, while older drugs fade away.

The pipeline is deep, with 16 brand-new products in Phase 3 studies. Pfizer expects to launch several new drugs by the end of the decade, which could help it recover even if sales dip while the cliffs hit.

Medtronic (MDT): Growth Without a Patent Cliff

Medtronic is the odd one out. As a medical device maker, it doesn’t depend on a single drug going off patent, and its recent story is about momentum rather than defense. After a weak first half of the year, the stock rebounded on strong results. In the first quarter of fiscal 2027, which ended July 31, revenue rose 13.7% to $9.8 billion.

Cardiac ablation, a procedure to fix irregular heart rhythms, is doing much of the heavy lifting, since Medtronic helped pioneer a newer technique. Its Hugo robotic-assisted surgery system, cleared in the U.S. last year, may take time to ramp up but addresses a large market. The company also completed the spin-off of its diabetes care unit, which had lower operating margins than the rest of the business.

Medtronic has raised its dividend for 49 consecutive years. Its yield is the lowest of the three, but it comes with the strongest recent growth.



NEXT: